**November 11, 2025 — Leads & Copy —** Alcon (SIX/NYSE:ALC) reported its financial results for the three and nine month periods ending September 30, 2025, with third-quarter sales reaching $2.6 billion, a 6% increase on a reported basis and a 5% increase on a constant currency basis compared to the same period last year.
The company’s diluted earnings per share were reported at $0.48, while core diluted earnings per share reached $0.79 for the third quarter of 2025.
David J. Endicott, Alcon’s Chief Executive Officer, noted encouraging topline growth in the third quarter, fueled by strong acceleration in equipment sales. He cited the increasing traction of Unity VCS across key markets and a strong order book. Endicott also expressed optimism about the positive reception of PanOptix Pro among surgeons and the promising early uptake of Tryptyr, which he believes sets a solid foundation for 2026.
Key financial figures for the third quarter and first nine months of 2025, as reported by Alcon:
- Net sales for the third quarter reached $2,589 million, compared to $2,433 million in 2024.
- Net sales for the first nine months totaled $7,617 million, up from $7,359 million in 2024.
- Operating margin for the third quarter was 12.8%, slightly down from 13.6% in the previous year.
- Operating margin for the first nine months was 13.7%, a slight decrease from 13.8% in 2024.
- Diluted earnings per share for the third quarter were $0.48, compared to $0.53 in 2024.
- Diluted earnings per share for the first nine months increased to $1.53 from $1.48 in the prior year.
- Core operating margin for the third quarter was 20.2%, slightly lower than the 20.6% reported in 2024.
- Core operating margin for the first nine months stood at 20.0%, compared to 20.8% in the previous year.
- Core diluted earnings per share for the third quarter were $0.79, down from $0.81 in 2024.
- Core diluted earnings per share for the first nine months were $2.29, slightly lower than the $2.33 reported in the previous year.
- Net cash flows from operating activities for the first nine months amounted to $1,613 million, consistent with the prior year.
- Free cash flow for the first nine months was $1,244 million, a decrease from $1,296 million in 2024.
In terms of sales by segment for the third quarter of 2025:
- Surgical net sales, encompassing implantables, consumables, and equipment/other, totaled $1.4 billion, marking a 6% increase on a reported basis and a 5% increase on a constant currency basis compared to the third quarter of 2024.
- Vision Care net sales, including contact lenses and ocular health, reached $1.2 billion, reflecting a 7% increase on a reported basis and a 5% increase on a constant currency basis compared to the third quarter of 2024.
For the first nine months of 2025:
- Surgical net sales amounted to $4.2 billion, a 3% increase on a reported and constant currency basis compared to the same period last year.
- Vision Care net sales totaled $3.4 billion, reflecting a 5% increase on a reported basis and a 4% increase on a constant currency basis compared to the first nine months of 2024.
Alcon maintained its full-year 2025 outlook, projecting net sales between $10.3 to $10.4 billion, a constant currency change versus the prior year of +4% to +5%, and core diluted EPS between $3.05 to $3.15, a constant currency change versus the prior year of 0% to +2%.
The company’s third-quarter 2025 press release, interim financial report, and supplemental presentation materials are available on Alcon’s Investor Relations website.
Source: Alcon
